Citadel Advisors’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-41,900
| Closed | -$1.99M | – | 12551 |
|
|
2025
Q3 | $1.99M | Sell |
41,900
-32,400
| -44% | -$1.57M | ﹤0.01% | 6079 |
|
|
2025
Q2 | $3.96M | Buy |
74,300
+63,900
| +614% | +$2.9M | ﹤0.01% | 4507 |
|
|
2025
Q1 | $421K | Sell |
10,400
-5,400
| -34% | -$229K | ﹤0.01% | 8858 |
|
|
2024
Q4 | $440K | Sell |
15,800
-25,400
| -62% | -$769K | ﹤0.01% | 8845 |
|
|
2024
Q3 | $1.18M | Sell |
41,200
-16,600
| -29% | -$433K | ﹤0.01% | 6527 |
|
|
2024
Q2 | $1.36M | Sell |
57,800
-19,400
| -25% | -$415K | ﹤0.01% | 6038 |
|
|
2024
Q1 | $1.95M | Sell |
77,200
-21,600
| -22% | -$519K | ﹤0.01% | 5571 |
|
|
2023
Q4 | $2.31M | Buy |
98,800
+63,100
| +177% | +$1.24M | ﹤0.01% | 5112 |
|
|
2023
Q3 | $1.81M | Buy |
35,700
+10,100
| +39% | +$470K | ﹤0.01% | 5407 |
|
|
2023
Q2 | $1.2M | Sell |
25,600
-27,300
| -52% | -$1.25M | ﹤0.01% | 6090 |
|
|
2023
Q1 | $2.02M | Sell |
52,900
-70,500
| -57% | -$3.14M | ﹤0.01% | 5345 |
|
|
2022
Q4 | $6.76M | Buy |
123,400
+51,700
| +72% | +$2.22M | ﹤0.01% | 3389 |
|
|
2022
Q3 | $2.44M | Buy |
+71,700
| New | +$1.1M | ﹤0.01% | 5203 |
|
|
2021
Q2 | – | Sell |
-13,400
| Closed | -$389K | – | 13592 |
|
|
2021
Q1 | $389K | Buy |
+13,400
| New | +$406K | ﹤0.01% | 10249 |
|
|
2020
Q2 | – | Sell |
-14,000
| Closed | -$297K | – | 9705 |
|
|
2020
Q1 | $297K | Buy |
+14,000
| New | +$300K | ﹤0.01% | 7354 |
|
Other funds holding AKRO
Citadel Advisors's AKRO Position: Q4 2025 in Review
Citadel Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 685,842 shares — an estimated $32.6M sold.
Citadel Advisors first reported a position in AKRO in Q3 2019 and held it in 24 quarters. The position peaked at $77.3M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Citadel Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 685,842 Akero Therapeutics shares in Q4 2025, an estimated $32.6M.
- Citadel Advisors first reported a position in Akero Therapeutics in Q3 2019 and held it in 24 quarters.
- Citadel Advisors's Akero Therapeutics position peaked at $77.3M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.